AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
GASTROTECH PHARMA, LILLY TO COMBAT DIGESTIVE CONDITIONS.
(Full text of a statement, contact details below)
COPENHAGEN, March 31 /PRNewswire-AsiaNet/ -- Gastrotech Pharma A/S has acquired an ongoing collaboration agreement with Eli Lilly and Company, (NYSE: LLY) to continue the development of proprietary peptides that treat irritable bowel syndrome (IBS) and functional dyspepsia, two common digestive diseases.
Gastrotech Pharma will continue the ongoing double-blind, placebo-controlled clinical Phase II trial of a glucagon-like peptide-1 (GLP-1) analogue in IBS patients with moderate to severe pain in five medical centers in Sweden and Denmark. Lilly will manufacture the clinical compound and has an option to further develop and commercialize products under the agreement. Specific financial terms of the agreement were not disclosed, but Gastrotech Pharma has the potential to receive milestone payments and royalties on sales.
"Lilly's experience in the GLP-1 field and its proven ability to develop and commercialize products have the potential to help Gastrotech deliver treatments that address important unmet medical needs for many people," said Dr. Claes Post, CEO at Gastrotech Pharma.
About GLP-1
Glucagon-like peptide-1 (GLP-1) is an endogenous peptide that acts by reducing gastrointestinal motor activity. Over-activity and the build-up of pressure in the gastrointestinal tract are believed to be the major contributing factors to pain occurring in IBS patients with diarrhea or constipation. Furthermore, the smooth muscle relaxing effect of GLP-1 has been shown to increase the compliance of the gastric ventricle, which is believed to be important for the relief of functional dyspepsia. Under the collaboration agreement between Gastrotech Pharma and Lilly a GLP-1 analogue is currently in a clinical Phase II double-blind, placebo-controlled trial in IBS patients with moderate to severe pain in five hospital centers in Sweden and Denmark.
About Irritable Bowel Syndrome
- Gastrotech Pharma and Lilly Form Collaboration to Combat Digestive Conditions.
- Press release article from: PR Newswire March 31, 2004 700+ words
...IBS) and functional dyspepsia, two common...diseases. Gastrotech Pharma will continue...the relief of functional dyspepsia. Under the...agreement between Gastrotech Pharma and Lilly a...or chest. Functional dyspepsia is not adequately...therapies. About ...
- Gastrotech Pharma A/S and Eli Lilly and Co form collaboration.(Brief Article)
- Newspaper article from: Nordic Business Report April 1, 2004 700+ words
...1 April 2004-Gastrotech Pharma A/S and Eli Lilly...biopharmaceutical company Gastrotech Pharma A/S said on Wednesday...syndrome (IBS) and functional dyspepsia, two common digestive...Under the agreement Gastrotech Pharma will continue the...
- DOR BioPharma Executes Letter of Intent for Acquisition of Gastrotech Pharma;...
- Press release article from: Business Wire November 2, 2005 700+ words
...that it has signed a binding letter of intent to acquire Gastrotech Pharma A/S ("Gastrotech"), a private Danish biotechnology...The product also has application in the treatment of functional dyspepsia. GLP-1 has been shown to reduce the gastrointestinal...
- Gastrotech and Lilly collaborate on digestive conditions.(Gastrotech Pharma...
- Newspaper article from: Pharma Marketletter April 5, 2004 700+ words
Denmark's Gastrotech Pharma A/S has acquired an ongoing collaboration agreement with...proprietary peptides that treat irritable bowel syndrome and functional dyspepsia, two common digestive diseases. Gastrotech will continue...
- Axcan: Functional Dyspepsia Drug Fails In Phase III Trial.
- Magazine article from: BIOWORLD Today Osborne, Randall February 23, 2006 700+ words
...s ITAX for functional dyspepsia fizzled in Phase...with regard to functional dyspepsia until further...in the area is Gastrotech Pharma A/S, of Copenhagen...may have use in functional dyspepsia. Late last year...
- Gastrotech Pharma A/S names Dr. Claes Post CEO and completes series A finance...
- Press release article from: PR Newswire November 12, 2003 700+ words
...November 12 /PRNewswire/ -- Gastrotech Pharma A/S announces today the appointment...position of Chief Executive Officer of Gastrotech Pharma A/S. Dr.Post has an outstanding...Chairman of the Board of Directors of Gastrotech Pharma says: "The addition of Dr.Post...
- Former Roche Head of CNS R&D Joins Gastrotech Pharma A/S Board of Directors.
- Press release article from: PR Newswire Europe October 18, 2004 700+ words
...Chairman of the Board of Directors of Gastrotech Pharma A/S adds: "Professor Bartfai is known...to his wide-spread network." About Gastrotech Pharma A/S Gastrotech Pharma A/S is a biopharmaceutical company focusing...
- Gastrotech Pharma A/S Names Dr. Claes Post CEO and Completes Series A Finance...
- Press release article from: PR Newswire November 12, 2003 700+ words
...Denmark, Nov. 12 /PRNewswire/ -- Gastrotech Pharma A/S announces today the appointment...position of Chief Executive Officer of Gastrotech Pharma A/S. Dr. Post has an outstanding...Chairman of the Board of Directors of Gastrotech Pharma says: "The addition of Dr. Post...